Keyword: San Diego

Mast Therapeutics in stormy waters after PhIII flop

Mast was down by more than 80% premarket this morning on the news that its late-stage sickle cell disease candidate vepoloxamer (MST-188) failed to beat placebo, as the biotech looks to cut the program, and its staff.